WuXi Biologics plans to build a comprehensive CRDMO centre in Singapore

27-Jul-2022

This investment will establish a cutting-edge, fully integrated CRDMO centre in Singapore and strenghten WuXi Biologics’ global research, development and manufacturing network

The CRDMO centre in Singapore will include a research and development service centre and large-scale drug substance and drug product manufacturing facilities for biologics.

The investment also strengthens WuXi Biologics’ global research, development and manufacturing network with more robust nodes to meet the growing demand from clients worldwide for end-to-end services, and continues to enable its Global Dual Sourcing strategy.

WuXi Biologics (“WuXi Bio”) (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced a 10-year USD$1.4 billion (S$2 billion) investment plan to expand the company’s research, development, and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore. This new site will add 120,000L biomanufacturing capacity to WuXi Biologics’ global network by 2026 and is anticipated to employ 1,500 research, development and manufacturing staff when complete.

Following the momentum of continued investments in the US, Ireland, Germany and China, this new addition in Singapore will become a critical part of the robust global supply chain network WuXi Biologics has established to fully meet the needs of global clients. The centre will also reinforce WuXi Biologics’ Global Dual Sourcing strategy, which ensures that customer projects can be fulfilled at multiple facilities globally to mitigate potential risks.

WuXi Biologics’ investment plan is supported by the Singapore Economic Development Board (EDB). “We warmly welcome WuXi Bio’s plan,” said Dr. Beh Swan Gin, Chairman of EDB. “The investments will establish Singapore as a significant node in the company’s global research, development and manufacturing network. It is a testament to Singapore’s position as a global biopharmaceutical hub, and will strengthen our attractiveness to biotech innovators and start-ups.”

Sign up for your free email newsletter

Dr. Chris Chen, CEO of WuXi Biologics, commented, “Singapore has established itself as one of the most advanced pharmaceutical hubs in the world. As a trusted partner to global healthcare companies and a strong contributor to the local community, WuXi Biologics’ investment in the new CRDMO centre will enhance the sustainable growth and success of the Singapore biotech ecosystem and enable the global biologics industry with a more robust supply chain. With the support of EDB and our local partners in Singapore, WuXi Biologics looks forward to moving ahead with this important project to enable global partners and benefit patients worldwide.”

Companies